Finding multiple sclerosis-like lesions on an MRI before experiencing any typical MS symptoms can feel like receiving a weather alert for a storm that mayor may notarrive. Radiologically isolated syndrome, commonly called RIS, occupies this uncomfortable space between an abnormal scan and a clinical neurological diagnosis.
Research from the TERIS randomized clinical trial offers a potentially important development. Investigators found that teriflunomide, an oral disease-modifying therapy already used for relapsing forms of multiple sclerosis, significantly delayed a first clinical demyelinating event in adults with RIS. The result does not mean everyone with RIS should immediately begin treatment, nor does it prove that teriflunomide permanently prevents MS. It does, however, strengthen the case for discussing early intervention in carefully selected people at higher risk.
What Is Radiologically Isolated Syndrome?
Radiologically isolated syndrome describes a situation in which an MRI reveals brain or spinal cord lesions that strongly resemble the inflammatory demyelinating lesions seen in multiple sclerosis, but the person has never experienced a typical MS attack or progressive neurological symptoms attributable to those lesions.
The scan is often ordered for an unrelated reason, such as migraines, dizziness, head trauma, hearing problems, or persistent headaches. Instead of finding the expected explanationor sometimes in addition to itthe radiologist notices white-matter abnormalities in locations commonly affected by MS.
RIS Is Not Simply “MS Without Symptoms”
An abnormal MRI alone is not enough to establish RIS. White-matter spots can occur with aging, migraines, vascular disease, infections, inflammatory disorders, genetic conditions, and several other causes. Neurologists must examine lesion shape, size, distribution, and appearance while ruling out reasonable alternative explanations.
The medical history and neurological examination also matter. A person with previous optic neuritis, a spinal cord syndrome, or another classic demyelinating attack may instead have clinically isolated syndrome or meet criteria for MS. In other words, MRI interpretation is not a neurological version of “spot the difference.” Context is essential.
Why RIS Deserves Attention
Some people with RIS never develop clinical MS, while others experience new MRI activity or neurological symptoms over time. Earlier natural-history research found that approximately one-third of people meeting the original RIS criteria developed an initial clinical event within five years, with the proportion rising during longer follow-up.
This wide range creates the central RIS dilemma: treating everyone may expose low-risk individuals to medication burdens they never needed, while treating no one may allow preventable inflammatory damage in those at high risk. Medicine occasionally serves a multiple-choice question in which every answer begins with “it depends.”
What the TERIS Trial Investigated
The TERIS trial was a multicenter, double-blind, placebo-controlled phase 3 study designed to determine whether teriflunomide could extend the time before a person with RIS experienced a first clinical event consistent with multiple sclerosis.
The study enrolled 89 adults who met the 2009 diagnostic criteria for RIS. Participants were randomly assigned to receive either 14 milligrams of oral teriflunomide once daily or a matching placebo. The primary study period lasted 96 weeks, with an option for follow-up extending to 144 weeks.
A clinical event was defined as an acute neurological symptom attributable to demyelination, typically lasting more than 24 hours, or a progressive neurological event developing over at least 12 months. Possible events included symptoms involving vision, sensation, strength, balance, coordination, the brainstem, or the spinal cord.
The Main Result: A Longer Time Before Symptoms
During follow-up, investigators recorded 28 first clinical events: 20 in the placebo group and eight in the teriflunomide group. After adjustment for relevant baseline factors, teriflunomide was associated with a 72% relative reduction in the risk of experiencing a first clinical demyelinating event compared with placebo.
The unadjusted analysis also favored treatment, showing a 63% relative risk reduction. Both analyses indicated that participants receiving teriflunomide generally remained free of clinical MS symptoms longer than those receiving placebo.
That is the headline, but statistical headlines need careful translation. A 72% relative risk reduction does not mean teriflunomide guarantees that 72 out of every 100 patients will avoid MS. It compares the rate of events between the treatment and placebo groups during the study period. Individual outcomes still depend on baseline risk, follow-up time, biology, adherence, and factors researchers may not yet fully understand.
Why the Findings Matter
Historically, neurologists often monitored RIS with repeat examinations and MRI scans rather than prescribing disease-modifying therapy before symptoms appeared. That conservative strategy remains reasonable for many people, especially when MRI findings are stable and risk factors are limited.
TERIS adds randomized evidence that treatment during the radiologically isolated phase can alter the timing of clinical disease. Together with the ARISE trial, which found that dimethyl fumarate also reduced the risk of a first clinical event in RIS, the study supports the idea that inflammatory MS biology may be modifiable before the first recognizable attack.
Earlier Treatment Could Protect Neurological Reserve
MS-related inflammation can occur silently. A new lesion may not produce obvious symptoms if it develops in a less clinically noticeable location or if the brain compensates for the damage. Nevertheless, repeated silent activity may gradually reduce neurological reservethe nervous system’s ability to adapt and keep functioning normally.
Delaying the first attack could therefore have value beyond postponing an unpleasant milestone. In theory, controlling inflammation earlier may preserve tissue and reduce the accumulation of lesions. However, the TERIS trial was not large or long enough to prove that teriflunomide prevents long-term disability in people with RIS. That important question remains open.
The MRI Results Were Less Conclusive
Although the primary clinical outcome favored teriflunomide, several secondary MRI outcomes did not reach statistical significance. Differences in new or enlarging T2 lesions, new contrast-enhancing lesions, and the proportion of participants with new lesions were not conclusive.
This does not erase the primary result, but it adds nuance. The study was relatively small, MRI protocols and event rates can influence statistical power, and a clinical benefit without clearly significant secondary imaging differences deserves further investigation. Science is rarely rude enough to fit every answer into one tidy chart.
Who With RIS May Face a Higher Risk of Developing MS?
Not every person with RIS has the same probability of developing clinical symptoms. Neurologists commonly consider several features when estimating risk and deciding whether monitoring or treatment makes more sense.
Important Risk Factors
- Younger age: Younger adults with RIS have generally shown a higher likelihood of clinical conversion during long-term follow-up.
- Spinal cord lesions: Demyelinating-appearing lesions in the cervical or thoracic spinal cord are among the more concerning predictors.
- Infratentorial lesions: Lesions in the brainstem or cerebellum may increase risk.
- Gadolinium-enhancing lesions: Enhancement suggests active inflammation at the time of the scan.
- New MRI activity: Additional or enlarging lesions on follow-up imaging indicate that the process is not radiologically quiet.
- CSF oligoclonal bands: These immune proteins, detected through lumbar puncture, can support evidence of central nervous system inflammation.
- Higher lesion burden: Numerous lesions in characteristic locations may influence the treatment discussion.
A single risk factor does not automatically dictate treatment. Clinicians usually evaluate the entire pattern, including the reliability of the RIS diagnosis, medical history, pregnancy plans, other health conditions, personal preferences, and willingness to accept medication monitoring.
How Teriflunomide Works
Teriflunomide is an oral immunomodulatory medication. It inhibits an enzyme called dihydroorotate dehydrogenase, which activated immune cells use to produce pyrimidines needed for rapid multiplication. By limiting this pathway, the medication reduces the expansion of activated T and B lymphocytes involved in inflammatory attacks on myelin.
The drug does not broadly erase the immune system, and resting cells can use alternative metabolic pathways. Even so, teriflunomide affects immune activity and requires appropriate screening, laboratory monitoring, and attention to infection risks.
In the United States, teriflunomide is approved for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Treating RIS specifically is an off-label decision that should be made with an MS specialist.
Benefits and Practical Advantages
Teriflunomide is taken once daily by mouth, which may appeal to people who prefer to avoid injections or infusion-center visits. It also has years of clinical experience in relapsing MS, so neurologists are familiar with its monitoring requirements, drug interactions, and adverse-effect profile.
For a person with high-risk RIS, the potential benefit is straightforward: delaying or preventing a first clinical demyelinating event during the treatment period. The less straightforward part is deciding whether that benefit outweighs the burdens of taking a long-term medication while feeling completely healthy.
Teriflunomide Risks and Monitoring
Teriflunomide is not a casual “just in case” vitamin. Its prescribing information includes boxed warnings for serious liver injury and embryofetal toxicity. Before treatment, clinicians typically review liver function, blood-cell counts, blood pressure, infection history, tuberculosis screening, medications, vaccination status, and reproductive plans.
Common Adverse Effects
Frequently reported side effects include headache, diarrhea, nausea, temporary hair thinning, and increased liver enzymes. Blood pressure may rise, and blood-cell counts can decline. Many adverse effects are manageable, but persistent or severe symptoms require medical evaluation.
Pregnancy and Reproductive Planning
Teriflunomide can harm a developing fetus and is contraindicated during pregnancy. Effective contraception and careful planning are essential for people who could become pregnant. Because teriflunomide may remain in the body for many months, clinicians can prescribe an accelerated elimination procedure using cholestyramine or activated charcoal when rapid removal is necessary.
Men taking teriflunomide should also discuss reproductive plans with their clinician because the medication is detectable in semen and the FDA label includes specific counseling considerations.
Rare but Serious Reactions
Potentially serious complications include severe liver injury, significant infections, peripheral neuropathy, serious allergic or skin reactions, blood disorders, and interstitial lung disease. New numbness, weakness, breathing difficulty, extensive rash, facial swelling, jaundice, dark urine, or persistent abdominal symptoms deserve prompt medical attention.
Limitations of the TERIS Study
The TERIS results are encouraging, but several limitations prevent the study from closing the RIS treatment debate.
First, the trial randomized only 89 participants. Small studies can identify meaningful treatment effects, but their estimates are less precise than findings from much larger trials. Second, follow-up was relatively short compared with the decades-long course of MS. Researchers cannot yet say whether delaying symptoms for a few years translates into less disability 10, 20, or 30 years later.
Third, the study used the 2009 RIS criteria. Revised 2023 criteria broadened and refined how RIS may be identified, so future research must determine how well the findings apply across newer diagnostic groups. Fourth, secondary MRI outcomes were not statistically significant. Finally, treatment can create a prevention paradox: a person who remains symptom-free may never know whether the drug worked or whether symptoms would never have developed anyway.
Treatment or Monitoring: Questions to Discuss With a Neurologist
The decision is not simply “take a pill” versus “do nothing.” Active monitoring is a legitimate management strategy that generally includes neurological examinations, brain MRI, and often spinal cord imaging. Some specialty centers repeat MRI every six to 12 months initially, adjusting the schedule according to stability and risk.
Useful questions for an appointment include:
- How confident are you that my lesions represent RIS rather than migraine, vascular changes, or another condition?
- Do I have spinal cord lesions, enhancing lesions, new lesions, or cerebrospinal fluid oligoclonal bands?
- What is my estimated risk of developing symptoms over the next two, five, and 10 years?
- Would teriflunomide be used off-label in my situation?
- What baseline tests and ongoing laboratory monitoring would I need?
- How would pregnancy plans or other medications affect the decision?
- What findings would cause us to start, switch, or stop treatment?
A second opinion from an MS neurologist can be particularly useful when the MRI pattern is uncertain or when treatment is being considered before symptoms have occurred.
Experiences Around RIS and Early Teriflunomide Treatment
The following scenarios are educational composites rather than accounts from named patients or TERIS trial participants. They illustrate common practical and emotional issues that may arise after an RIS diagnosis.
The Incidental MRI Surprise
Imagine a 31-year-old professional who undergoes an MRI because migraines have recently become more frequent. The headaches turn out to be manageable, but the scan reveals several periventricular lesions and one lesion near the corpus callosum. A follow-up spinal MRI finds a small cervical cord lesion. The neurological examination is normal, and there is no history of optic neuritis, prolonged numbness, weakness, or balance loss.
The first reaction may be disbelief: “I came in because lights were annoying, and now we are discussing multiple sclerosis?” That emotional whiplash is common in incidental findings. RIS can produce anxiety precisely because the person feels well while being asked to contemplate a disease that has not clinically appeared.
After additional testing reveals cerebrospinal fluid oligoclonal bands, the neurologist explains that the combination of younger age, a spinal cord lesion, and inflammatory markers places the patient in a higher-risk category. Teriflunomide becomes one reasonable option, but so does close MRI surveillance. The decision may depend as much on the person’s risk tolerance and reproductive plans as on the scan itself.
Learning to Live With Monitoring
Another person, age 52, has a few stable brain lesions discovered during a hearing evaluation. There are no spinal lesions, no enhancing areas, a normal examination, and no new changes after one year. This patient chooses monitoring rather than medication.
At first, every tingling finger feels ominous. After several appointments, the patient learns that sleeping on an arm, anxiety, vitamin deficiencies, pinched nerves, and ordinary human wear-and-tear still existeven after someone has mentioned MS. A clear plan helps: report persistent focal neurological symptoms, attend scheduled examinations, and avoid turning every muscle twitch into a midnight internet detective series.
Starting an Oral Therapy While Feeling Healthy
A third patient chooses teriflunomide after new lesions appear on a six-month MRI. The practical experience begins with blood tests, blood-pressure measurement, medication review, infection screening, and a serious conversation about contraception.
During the first months, the patient notices mild diarrhea and increased hair shedding. Neither is delightful, but both improve with time and clinical guidance. Monthly liver tests become part of the calendar, filed somewhere between dental cleaning and “remember to buy coffee.” The hardest part is psychological: taking medication daily without having symptoms makes the benefit invisible.
Follow-up MRI scans remain stable, and no clinical attack occurs. This outcome is encouraging, but it cannot prove what would have happened without therapy. The patient and neurologist therefore evaluate the decision periodically rather than treating the original choice as permanent or sacred.
Pregnancy Plans Change the Conversation
For someone hoping to become pregnant soon, the risk-benefit calculation may look very different. Teriflunomide’s fetal risks and prolonged elimination mean that reproductive timing must be discussed before the first dose, not after a positive pregnancy test creates an emergency scramble.
The neurologist may recommend monitoring, another strategy, or a carefully timed accelerated elimination procedure. The lesson is not that pregnancy automatically rules out proactive RIS management. It means treatment selection must fit the patient’s actual life rather than an imaginary person who has no plans, preferences, other illnesses, or inconveniently complicated biology.
The Shared Theme: Uncertainty With a Plan
These experiences share one theme: RIS introduces uncertainty, but uncertainty does not have to mean helplessness. A thoughtful plan may include repeat MRI scans, symptom education, correction of vitamin deficiencies, smoking cessation, regular physical activity, management of vascular risks, and a personalized discussion about disease-modifying treatment.
TERIS gives patients and clinicians better evidence for that discussion. It does not replace individual judgment, and it does not turn every incidental lesion into a prescription. Instead, it provides another tool for matching the intensity of treatment to the estimated risk.
Conclusion
The TERIS trial provides important evidence that once-daily teriflunomide may delay the first clinical symptoms of multiple sclerosis in adults with radiologically isolated syndrome. The adjusted analysis showed a 72% relative reduction in the risk of a first clinical demyelinating event compared with placebo, supporting the broader concept that MS-related inflammation may be treatable before symptoms begin.
Still, the findings do not establish that everyone with RIS should take teriflunomide. The study was small, long-term disability benefits remain unknown, MRI secondary outcomes were inconclusive, and the medication carries meaningful liver, pregnancy, infection, nerve, and other safety considerations.
The most appropriate next step is individualized risk assessment with an experienced neurologist. For some people, structured monitoring will remain the best choice. For othersparticularly younger patients with spinal lesions, active MRI changes, enhancing lesions, or cerebrospinal fluid oligoclonal bandsthe potential advantages of early treatment may be compelling enough to justify its burdens.
